Papers/PMID:30661700
Vitamin A treatment for severe sepsis in humans; a prospective randomized double blind placebo-controlled clinical trial.
Clinical nutrition ESPEN2019The record
2 findings · 1 compound · 2 endpoints · 1 null
What it reported
How to read these marksWhat moved
1 finding
all-trans-retinol — increases serum albumin
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Finding“Serum albumin measured as part of the APACHE III score was increased in the vitamin A group as compared to the placebo group at Day 14 (See Table 2).”
Quoted verbatim from Vitamin A treatment for severe sepsis in humans; a prospective randomized double blind placebo-controlled clinical trial.. - Study
- RCT
- Duration
- 14 days
- Dose
- 100,000 IU daily for 7 days, intramuscular injection, versus placebo injection
- Population
- Adults with severe sepsis or septic shock in an ICU; day 14 value
Vitamin A treatment for severe sepsis in humans; a prospective randomized double blind placebo-controlled clinical trial.2019PMID:30661700Industry fundedPermalink
What did not
1 finding
all-trans-retinol — no detected effect on intensive care unit length of stay
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.FindingNull result“The average number of days on blood pressure agents, stay in the ICU and days of ventilator were similar between the Vitamin A and Placebo treated groups.”
Quoted verbatim from Vitamin A treatment for severe sepsis in humans; a prospective randomized double blind placebo-controlled clinical trial.. - Study
- RCT
- Duration
- 7 days
- Dose
- 100,000 IU daily for 7 days, intramuscular injection, versus placebo injection
- Population
- Adults with severe sepsis or septic shock in an ICU
Vitamin A treatment for severe sepsis in humans; a prospective randomized double blind placebo-controlled clinical trial.2019PMID:30661700Industry fundedPermalink